Targeting type I collagen for cancer treatment. Issue 5 (8th March 2022)

• Record Type: Journal Article
• Authors: Shi, Run; Zhang, Zhe; Zhu, Ankai; Xiong, Xingxing; Zhang, Jie; Xu, Jiang; Sy, Man‐Sun; Li, Chaoyang
• Is Part Of: International journal of cancer. Volume 151:Issue 5(2022)
• Page Start: 665
• Page End: 683
• Publication Date: 2022-03-08
• Subjects: biosynthesis -- cancer progression -- inhibitors -- type I collagen; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.33985
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: Collagen is the most abundant protein in animals. Interactions between tumor cells and collagen influence every step of tumor development. Type I collagen is the main fibrillar collagen in the extracellular matrix and is frequently upregulated during tumorigenesis. The binding of type I collagen to its receptors on tumor cells promotes tumor cell proliferation, epithelial‐mesenchymal transition and metastasis. Type I collagen also regulates the efficacy of tumor therapies, such as chemotherapy, radiotherapy and immunotherapy. Furthermore, type I collagen fragments are diagnostic markers of metastatic tumors and have prognostic value. Inhibition of type I collagen synthesis has been reported to have antitumor effects in animal models. However, collagen has also been shown to possess antitumor activity. Therefore, the roles that type I collagen plays in tumor biology are complex and tumor type‐dependent. In this review, we discuss the expression and regulation of synthesis of type I collagen, as well as the role upregulated type I collagen plays in various stages of cancer progression. We also discuss the role of collagen in tumor therapy. Finally, we highlight several recent approaches targeting type I collagen for cancer treatment. Abstract :